From Lab to Market: The Journey of Diagnostics and the Importance of Regulatory Compliance

The development and use of diagnostics play a crucial role in modern healthcare. These innovative tools enable early detection, accurate diagnoses, and personalized treatment plans, leading to improved patient outcomes. However, before diagnostics can reach the market, they must undergo rigorous clinical investigations to ensure safety, efficacy, and reliability. This is where regulatory compliance comes into play—a vital aspect of the diagnostic development process that warrants thorough understanding and adherence. Here, we will explore the significance of regulatory compliance in clinical investigations for diagnostics and its impact on advancing healthcare.

The landscape of regulatory requirements for diagnostic clinical investigations is complex, involving multiple agencies and guidelines. In the United States, the Food and Drug Administration (FDA) holds authority over the regulation of medical devices, including diagnostics. In Europe, the European Union’s In Vitro Diagnostic Regulation (IVDR) serves as the primary framework for diagnostic medical devices. Compliance with these regulations is essential to ensure that diagnostics are safe, effective, and meet the necessary quality standards.

Protecting Patient Safety

Before the establishment of current-day regulatory compliance, ensuring patient safety in clinical trials was a less structured and standardized process. The historical practices varied significantly across different time periods and regions.

Key approaches included ethical principles that emphasized the importance of consent, voluntary participation, and the duty of researchers to prioritize the welfare of participants such as the Nuremberg Code (1947) and the Declaration of Helsinki (1964); ethics committees known as institutional review boards (IRBs) who reviewed research protocols to ensure ethical standards and minimal participant risk; and the medical professionals involved in clinical trials were responsible for monitoring and evaluating safety and well-being of enrolled patients. 

Despite these measures, it is important to acknowledge that the oversight of patient safety was less comprehensive compared to the current regulatory compliance landscape. The implementation of regulations, guidelines, and good clinical practice (GCP) principles now forms the foundation of contemporary patient safety oversight.

These regulations mandate rigorous study design, data collection, and reporting standards to ensure that the risks and benefits of investigational interventions are properly assessed and monitored throughout the trial leading to more rigorous and standardized processes in clinical investigations today. 

Ensuring Diagnostic Efficacy

Another crucial aspect of regulatory compliance is to provide valuable data on the performance and safety of diagnostics, and to allow regulators to assess potential risks and benefits before they reach the market. By adhering to regulatory guidelines, manufacturers can generate robust clinical data that supports the claims of their diagnostics.

This evidence-based approach helps healthcare providers make informed decisions, leading to accurate diagnoses and appropriate treatment interventions. Ultimately, regulatory compliance enhances the overall efficacy of diagnostics, benefiting patients and healthcare systems alike.

Facilitating Market Access

Regulatory compliance is an indispensable requirement for market access. Failure to comply with the necessary regulations can result in delays, financial losses, and potential reputational damage for diagnostic manufacturers. By meeting regulatory standards, manufacturers can demonstrate the safety and effectiveness of their diagnostics, enhancing their chances of receiving regulatory approvals. Successful market access enables wider availability of innovative diagnostic tools, ensuring patients have timely access to life-saving tests, treatments, and interventions.

Staying Up-to-Date with Evolving Regulations

Regulatory compliance in clinical investigations for diagnostics is a dynamic landscape that continually evolves to keep pace with scientific advancements and changing healthcare needs. Manufacturers must stay vigilant and adapt to these changes to remain compliant. This entails ongoing monitoring of regulatory updates, engaging with regulatory agencies, and participating in industry discussions and conferences. By staying up-to-date, manufacturers can proactively address regulatory requirements and maintain compliance, ensuring the development and availability of cutting-edge diagnostics.

Challenges and Future Perspectives

While regulatory compliance is crucial, it can pose challenges for diagnostic manufacturers. The process of conducting clinical investigations and navigating regulatory frameworks requires substantial resources, time, and expertise. Smaller companies and startups may face additional hurdles due to limited resources and expertise. However, collaborations and partnerships between manufacturers, research institutions, regulatory bodies, and clinical research organizations (CROs) can help overcome these challenges. Such collaborations promote knowledge sharing, foster innovation, and streamline the regulatory compliance process, ultimately benefiting patients and advancing healthcare.


Regulatory compliance is a cornerstone of clinical investigations for diagnostics, ensuring patient safety, diagnostic efficacy, and market access. Through compliance, diagnostic manufacturers demonstrate their commitment to upholding the highest standards and generating reliable clinical evidence. The regulatory landscape is ever-evolving, demanding constant vigilance and adaptation. By embracing these challenges and working collaboratively, the diagnostic industry can continue to develop and deliver innovative tools that transform healthcare, improving patient outcomes and contributing to the advancement of medical science.

ColoPlex Biomarker Data Published in Journal of Clinical Oncology

Abstract. Background: Colorectal cancer (CRC) is the third most common cancer worldwide motivating national screening strategies utilizing fecal immunochemical tests (FIT). Blood-based biomarkers could be an alternative method to increase compliance in population-based screening programs for early detection of CRC. We aimed to identify new blood-based biomarkers that could be potential candidates for use in colorectal cancer screening.



The development and commercialization of medical devices, including diagnostics, require a significant investment of time, resources, and expertise. To navigate the complex regulatory approval process and bring a device to market, many medical device companies partner with contract research organizations (CROs). In this article, we will explore the role of CROs in the diagnostics industry, the benefits of working with a CRO, and the different services that CROs provide to help companies bring their diagnostic devices to market.

AACC 2022

Want to chat with us during AACC? We want to see you in Chicago. Use the link below to schedule time with EDP during the show.   We'd love to schedule some time to meet you at AACC next week. In attendance will be Eric Mayer, CEO, Jon Dancy our Business Development...

Luminex Partner Spotlight

Luminex Partner Spotlight

Early detection makes a real difference in outcomes for cancer patients. But for cases of colorectal cancer, detecting tumors in the earliest stages has been virtually impossible. The team at EDP Biotech is committed to changing that by developing a simple, accurate, blood-based diagnostic test for biomarkers of colorectal cancer.

By Abby Kousouris Published: Aug. 17, 2021 at 7:25 PM EDT KNOXVILLE, Tenn. (WVLT) - A local Knoxville company says they’re seeing more demand for COVID-19 testing. EDP Biotech Corporation has different options available for people who want to find out if they have...

Contact us

Call Us

(255) 352-6258

Email Us

Our Location

5678 Extra Rd. #123
San Francisco, CA 96120

Get in touch